[Carboxyl-11 C]Labelling of Four High-Affinity cPLA2α Inhibitors and Their Evaluation as Radioligands in Mice by Positron Emission Tomography

A General and Scalable Synthesis of Polysubstituted Indoles

A consecutive 2-step synthesis of N-unprotected polysubstituted indoles bearing an electron-withdrawing group at the C-3 position from readily available nitroarenes is reported. The protocol is based on the [3,3]-sigmatropic rearrangement of N-oxyenamines generated by the DABCO-catalyzed reaction of N-arylhydroxylamines and conjugated terminal alkynes, and delivers indoles endowed with a wide array of substitution patterns and topologies.

Copper(I)-Mediated 11C-Carboxylation of (Hetero)arylstannanes

A novel copper-mediated carboxylation strategy of aryl- and heteroaryl-stannanes is described. The method serves as a mild (i.e., 1 atm) carboxylation method using stable carbon dioxide and is transferable as a radiosynthetic approach for carbon-11-labeled aromatic and heteroaromatic carboxylic acids using sub-stoichiometric quantities of [¹¹C]CO₂. The methodology was applied to the radiosynthesis of the retinoid X receptor agonist, [¹¹C]bexarotene, with a decay-corrected radiochemical yield of 32 ± 5% and molar activity of 38 ± 23 GBq/μmol (n = 3).

The development of 11C-carbonylation chemistry: A systematic view

The prospects for using carbon-11 labelled compounds in molecular imaging has improved with the development of diverse synthesis methods, including ¹¹C-carbonylations and refined techniques to handle [¹¹C]carbon monoxide at a nanomole scale. Facilitating biological research and molecular imaging was the driving force when [¹¹C]carbon monoxide was used in the first in vivo application with carbon-11 in human (1945) and when [¹¹C]carbon monoxide was used for the first time as a chemical reagent in the synthesis of [¹¹C]phosgene (1978). This review examines a rich plethora of labelled compounds synthesized from [¹¹C]carbon monoxide, their chemistry and use in molecular imaging. While the strong development of the ¹¹C-carbonylation chemistry has expanded the carbon-11 domain considerably, it could be argued that the number of ¹¹C-carbonyl compounds entering biological investigations should be higher. The reason for this may partly be the lack of commercially available synthesis instruments designed for ¹¹C-carbonylations. But as this review shows, novel and greatly simplified methods to handle [¹¹C]carbon monoxide have been developed. The next important challenge is to make full use of these technologies and synthesis methods in PET research. When there is a PET-tracer that meets a more general need, the incentive to implement ¹¹C-carbonylation protocols will increase.

[11C]Carbon monoxide: advances in production and application to PET radiotracer development over the past 15 years

[¹¹C]Carbon monoxide is an appealing synthon for introducing carbon-11 at a carbonyl position (C=O) in a wide variety of chemotypes (e.g., amides, ketones, acids, esters, and ureas). The prevalence of the carbonyl group in drug molecules and the present-day broad versatility of carbonylation reactions have led to an upsurge in the production of this synthon and in its application to PET radiotracer development. This review focuses on the major advances of the past 15 years.

Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A2

Phospholipase A2 (PLA2) enzymes are involved in various inflammatory pathological conditions including arthritis, cardiovascular and autoimmune diseases. The regulation of their catalytic activity is of high importance and a great effort has been devoted in developing synthetic inhibitors. We summarize the most important small-molecule synthetic PLA2 inhibitors developed to target each one of the four major types of human PLA2 (cytosolic cPLA2, calcium-independent iPLA2, secreted sPLA2, and lipoprotein-associated LpPLA2). We discuss recent applications of inhibitors to understand the role of each PLA2 type and their therapeutic potential. Potent and selective PLA2 inhibitors have been developed. Although some of them have been evaluated in clinical trials, none reached the market yet. Apart from their importance as potential medicinal agents, PLA2 inhibitors are excellent tools to unveil the role that each PLA2 type plays in cells and in vivo. Modern medicinal chemistry approaches are expected to generate improved PLA2 inhibitors as new agents to treat inflammatory diseases.